Evolus up 8% premarket on AbbVie’s Allergan bid

Evolus (NASDAQ:EOLS) is up 8% premarket, albeit on light volume, on the heels of AbbVie’s $63B bid for BOTOX maker Allergan.

In May, the FDA approved Jeuveau, its product for the treatment of frown lines.

https://seekingalpha.com/news/3473509-evolus-8-percent-premarket-abbvies-allergan-bid